



Mind the Gap


The EU's Struggle to Bridge Neurotech and Healthcare

"How do clinical, economic, societal, and legal factors affect the integration of emerging health technologies - such as AI diagnostics, brain-machine interfaces, and CRISPR-Cas9 - into neurological healthcare in the European Union?"

RELEVANCE:


Neurological diseases are

- leading cause of disability
- second leading cause of death




METHODOLOGY:

- 1. HTA FRAMEWORK
- 2. **EXPERT INTERVIEWS**: Dr. Pauly Ossenblok (Neurotech entrepreneur), Dr. Bart Mersseman (European Commission medical regulator), Prof. Dr. Tim Vanmierlo (CRISPR researcher)
- 3. SURVEY: 530+ respondents across the EU



Survey Respondent Nationalities (N = 535)



RESULTS:

CLINICAL EFFECTIVENESS

- Al: ready for use
- BMIs & CRISPR: promising

ECONOMIC VIABILITY

High costs & limited funding



SOCIETAL & ETHICAL ACCEPTANCE

• Public: cautious on new tech



LEGAL CHALLENGES

Al Act, Medical Devices
Regulation, GDPR

Conclusions: the challenge for Europe is three-fold:





2. Collective Trust



3. Innovation